How Will The Failure Of Biogen ' s Alzheimer ' s Drug, Aducanumab, Impact R & D?
The death of an important drug like aducanumab will have both a short and a long term effect on Biogen as a company and especially on R&D.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: John LaMattina, Contributor Source Type: news
More News: Alzheimer's | Pharmaceuticals